Systemic Management for Nonmetastatic Castration-resistant Prostate Cancer
Authors:
- 17 January 2020
- journal article
- review article
- Published by Wolters Kluwer Health in American Journal of Clinical Oncology
- Vol. 43 (4) , 288-297
Abstract
Purpose: To indirectly compare the efficacy and safety of systemic therapies used for patients with nonmetastatic castration-resistant prostate cancer (nmCRPC). Methods: The relevant randomized controlled trials were retrieved from PubMed and the Cochrane Library. Network meta-analyses were used to compare multiple drugs simultaneously for the outcomes of nmCRPC. Direct evidence in trials and indirect evidence across trials were combined by the network meta-analyses to estimate the treatment efficiency. Outcome: Eight studies were included in our research. For prostate-specific antigen progression-free survival, the rate of progression was significantly decreased following apalutamide, enzalutamide, bicalutamide+dutasteride, and bicalutamide treatment compared with placebo. Compared with placebo treatment, metastases-free survival was significantly increased in patients who received apalutamide (hazard ratio [HR]: 0.28, 95% confidence interval [CI]: 0.23-0.35), enzalutamide (HR: 0.29, 95% CI: 0.24-0.35), and darolutamide (HR: 0.42, 95% CI: 0.35-0.50). Direct comparison showed significant survival benefits in patients who received second-generation anti-androgen therapy (apalutamide, enzalutamide, and darolutamide: HR: 0.74, 95% CI: 0.61-0.91) compared with patients who received placebo. With respect to metastases-free survival, based on SUCRA analysis, there was 80% and 78% probability that apalutamide and enzalutamide were preferred treatment, while darolutamide was likely to be second-best choice. Compared with placebo, all agents were not associated with significantly higher likelihood of serious adverse events and grade 3 to 4 adverse events. Conclusion: Our outcomes support equivalent efficacy and similar risk of adverse effects between apalutamide, enzalutamide, and darolutamide, supporting the use of these antiandrogen agents in high-risk of progression nmCRPC.Keywords
This publication has 43 references indexed in Scilit:
- Time-to-event Outcomes in Men with Nonmetastatic Castrate-resistant Prostate Cancer—A Systematic Literature Review and Pooling of Individual Participant DataEuropean Urology Focus, 2019
- Metastatic Prostate CancerNew England Journal of Medicine, 2018
- Population‐Based External Validation of the Updated 2012 Partin Tables in Contemporary North American Prostate Cancer PatientsThe Prostate, 2016
- Variation in the use of postoperative radiotherapy among high-risk patients following radical prostatectomyProstate Cancer and Prostatic Diseases, 2016
- Declining Use of Radiotherapy for Adverse Features After Radical Prostatectomy: Results From the National Cancer Data BaseEuropean Urology, 2015
- Current Clinical Presentation and Treatment of Localized Prostate Cancer in the United StatesJournal of Urology, 2014
- Factors associated with initial treatment and survival for clinically localized prostate cancer: results from the CDC-NPCR Patterns of Care Study (PoC1)BMC Cancer, 2010
- Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate CancerScience, 2009
- Biology of Progressive, Castration-Resistant Prostate Cancer: Directed Therapies Targeting the Androgen-Receptor Signaling AxisJournal of Clinical Oncology, 2005
- Natural History of Rising Serum Prostate-Specific Antigen in Men With Castrate Nonmetastatic Prostate CancerJournal of Clinical Oncology, 2005